Zura Bio Limited (NASDAQ:ZURA - Get Free Report) EVP Kiran Nistala purchased 3,195 shares of Zura Bio stock in a transaction dated Monday, April 22nd. The shares were purchased at an average cost of $3.13 per share, with a total value of $10,000.35. Following the acquisition, the executive vice president now owns 3,195 shares of the company's stock, valued at approximately $10,000.35. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.
Zura Bio Trading Down 4.9 %
Shares of ZURA stock opened at $3.31 on Thursday. Zura Bio Limited has a 1 year low of $2.00 and a 1 year high of $14.00. The stock has a fifty day moving average of $3.21 and a two-hundred day moving average of $4.04.
Analyst Ratings Changes
Separately, Oppenheimer reiterated an "outperform" rating and issued a $16.00 price objective (down from $17.00) on shares of Zura Bio in a research report on Monday, April 1st. Four investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat.com, Zura Bio currently has a consensus rating of "Buy" and an average price target of $16.40.
Get Our Latest Stock Report on Zura Bio
Institutional Investors Weigh In On Zura Bio
Gold Mania
From Stansberry Research | Ad
Former Goldman VP Reveals Mysterious "Gold Bank" With Huge Upside Potential
He says the gains in this should be far greater than just bullion or mining stocks. Some folks had the chance to see 995% the last time we shared this exact "bank". Most people know nothing about it (except the rich and elite).
See his free reveal right here.
A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Lynx1 Capital Management LP bought a new position in Zura Bio in the 3rd quarter valued at about $65,000. Forefront Analytics LLC acquired a new stake in shares of Zura Bio in the 3rd quarter worth approximately $95,000. Bank of New York Mellon Corp bought a new position in shares of Zura Bio in the third quarter valued at approximately $224,000. Raymond James & Associates increased its stake in shares of Zura Bio by 14.0% during the third quarter. Raymond James & Associates now owns 77,356 shares of the company's stock valued at $511,000 after acquiring an additional 9,481 shares during the period. Finally, Eisler Capital US LLC bought a new stake in Zura Bio during the third quarter worth approximately $660,000. 61.14% of the stock is currently owned by institutional investors.
Zura Bio Company Profile
(
Get Free Report)
Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
